There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kaleido Biosciences Inc (KLDO) and Thermo Fisher (TMO) with bullish sentiments.
Kaleido Biosciences Inc (KLDO)
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Kaleido Biosciences Inc today and set a price target of $17.50. The company’s shares closed last Monday at $5.25, close to its 52-week low of $4.80.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 16.4% and a 48.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Applied Genetic Technologies, and Catalyst Biosciences Inc.
Kaleido Biosciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.
See today’s analyst top recommended stocks >>
Thermo Fisher (TMO)
In a report released today, Stephen Unger from Needham maintained a Buy rating on Thermo Fisher, with a price target of $321.00. The company’s shares closed last Monday at $280.99.
According to TipRanks.com, Unger is a 3-star analyst with an average return of 7.7% and a 56.7% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Genomic Health, and Veracyte.
Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $312.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
